This compound was used to generate and characterize a rat model with secondary carnitine deficiency due to inhibition of OCTN2 and γ-butyrobetaine hydroxylase, the last enzyme of the carnitine biosynthesis pathway (Vaz and Wanders, 2002). The gene discussed is SLC22A5; the disease is systemic primary carnitine deficiency disease.